文献速递耳科与耳神经小儿耳鼻咽喉头颈外科

儿童顺铂耳毒性防护:将硫代硫酸钠纳入日常临床实践

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.
PubMed 文献 · Ear Hear · 2026-06-26

国际儿童肿瘤耳毒性预防工作组基于现有证据与专家共识,针对儿童局部非转移性实体瘤接受顺铂治疗时使用硫代硫酸钠(STS)耳保护,识别出九项实施挑战并提出实用解决步骤与推荐声明,以促进STS在儿科临床中的常规应用。

要点

  • STS已获FDA、EMA和MHRA批准用于儿童局部非转移性实体瘤顺铂耳保护。
  • 工作组识别九项实施挑战,包括顺铂输注与STS给药时机、方案整合、药物相互作用及经济考量。
  • 基于文献与专家意见提出实用步骤和推荐声明,以促进STS临床实施。

核心结论

  • 工作组提出基于现有文献和专家意见的实用步骤与推荐声明,以促进STS在儿童局部非转移性实体瘤中的实施。

研究设计与样本

  • 国际儿童肿瘤耳毒性预防工作组由儿科肿瘤学、听力学和药理学专家组成,通过多次线上会议和2024年5月米兰SIOPE年会工作组会议形成推荐。

主要发现

  • 工作组识别出九项关键挑战,包括顺铂输注与STS给药的时机、STS整合入现有治疗方案、潜在药物相互作用及相关经济考量。

关键数值与推荐

  • STS已获FDA、EMA和MHRA批准作为耳保护剂,用于接受顺铂治疗的局部非转移性实体瘤儿童患者。

临床怎么用

  • 临床可参考工作组提出的实用步骤和推荐声明,在儿科日常实践中实施STS耳保护。

局限性

  • 部分推荐基于证据较少领域的共识而非稳健数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Sodium thiosulfate (STS) has recently been approved as an otoprotectant for systemic use in pediatric cancer patients receiving cisplatin treatment for localized, nonmetastatic solid tumors by the Food and Drug Administration, European Medicines Agency, and Medicines and Healthcare Products Regulatory Agency. While incorporating STS into the current standard of care pediatric practice, questions about uniform, timely, and safe administration are raised that may benefit from additional guidance. DESIGN: Recognizing that advancing clinical practice presents multiple challenges, an international onco-ototoxicity prevention task force, including experts in pediatric oncology, audiology, and pharmacology, was established to identify potential barriers to the implementation of otoprotection and to offer practical solutions for clinical services for children exposed to cisplatin, based on available evidence, as well as consensus where data are less robust. This task force held several online meetings and a working group session at the annual SIOPE meeting in Milan in May 2024, where the challenges for implementing STS were outlined and addressed. RESULTS: Nine key challenges were identified, including, for example, the timing of both cisplatin infusion and STS administration, the optimal integration of STS into existing treatment protocols, potential drug interactions, and relevant economic considerations. CONCLUSION: In this article, we propose practical steps to address these challenges, informed by the existing literature and expert opinion, incorporating recommendation statements from the international onco-ototoxicity prevention task force on behalf of the SIOP Supportive Care Network, to facilitate the implementation of STS in children with localized, nonmetastatic disease.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Streefkerk N, Geller JI, Knight K, et al. Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network. Ear Hear. 2026. PMID: 42370844. doi:10.1097/AUD.0000000000001856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。